#Advanced NanoTherapies #drug-coated balloon #vascular therapy

Funding Announcement by Advanced NanoTherapies

Advanced NanoTherapies, Inc. (ANT) has successfully raised over $31 million in a Series B funding round aimed at pioneering advancements in vascular therapy. This groundbreaking initiative introduces the SirPlux Duo, an innovative drug-coated balloon (DCB) that utilizes a novel nanoparticle delivery system to administer two chemotherapeutic agents, paclitaxel and sirolimus, directly into the vessel wall.

This funding round, which was oversubscribed, was supported by an undisclosed strategic investor alongside S3 Ventures, and included participation from T45 and several existing investors. The proceeds are set to accelerate the clinical advancements of coronary interventions and expand applications for below-the-knee (BTK) treatments.

The dual-drug device distinguishes itself in the market by enhancing the therapeutic effects compared to traditional DCBs that employ a single crystalline drug. According to Marwan Berrada-Sounni, CEO of ANT, this funding comes at a pivotal moment as first-generation DCBs continue to face limitations due to passive delivery mechanisms of crystalized drugs.

Revolutionary Approach to Vascular Interventions

The SirPlux Duo technology aims to address significant clinical challenges such as restenosis following percutaneous coronary interventions (PCI). Dr. Rishi Puri, a cardiologist at Cleveland Clinic and part of the team behind this technology, explained that their platform enables simultaneous delivery of two drugs at the lesion site using functionalized nanoparticles, resulting in minimized dosing while ensuring prolonged localized retention.

In essence, the SirPlux Duo allows clinicians to achieve higher therapeutic efficacy with lower dosages, thereby reducing downstream particle burden and preserving future treatment options for coronary and peripheral vascular diseases. As noted by Dr. Azeem Latib, this dual-drug delivery system represents a substantial advancement in vascular intervention, promising results that are comparable to drug-eluting stents while adhering to a